LakeShore Biopharma (LSB) has released an update.
LakeShore Biopharma has reported a rise in gross margin to 79.5% for Fiscal Year 2024, despite a decrease in revenue due to supply chain issues impacting their rabies vaccine production. The company has successfully resolved inventory challenges and anticipates double-digit revenue growth with a breakeven bottom line for Fiscal Year 2025. Advances in their product pipeline, including the PIKA rabies vaccine and other biologics for infectious diseases and cancer, are also highlighted as part of LakeShore’s strategic focus on innovation and shareholder value.
For further insights into LSB stock, check out TipRanks’ Stock Analysis page.
